GlassScriptPhysician profile
Allison Leigh Verity
NPI 1336761626
$1,765.86
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $80.39 · 2023: $1,131 · 2024: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,685.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $383.66 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $267.98 | 2022-2024 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $192.44 | 2023-2024 | Entyvio, Eohilia |
| Celgene Corporation | $176.55 | 2023-2024 | Zeposia |
| Gilead Sciences, INC. | $175.55 | 2023-2024 | |
| Janssen Biotech, INC. | $116.94 | 2022-2024 | Stelara, Tremfya, Simponi |
| Phathom Pharmaceuticals, INC. | $81.99 | 2023-2024 | Voquezna |
| Ardelyx, INC. | $72.45 | 2023-2024 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $52.97 | 2023 | Linzess |
| Qol Medical, LLC | $52.28 | 2023-2024 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $51.01 | 2023 | Sutab |
| Pfizer INC. | $45.60 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $21.76 | 2023 | Kristalose |
| Alnylam Pharmaceuticals INC. | $21.12 | 2023 | Givlaari |
| Lilly USA, LLC | $20.80 | 2024 | Omvoh |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $16.67 | 2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $16.09 | 2023 | Ocaliva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Verity listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.